insights_auto
Why is ONC up 4,23%?
Dive Deeperchevron_right
ONC:NASDAQ
BeOne Medicines AG
365,67 $
arrow_upward
+4,23%(+14,83) 1D
363,50 $
arrow_downward
-0,59% (-2,17)bedtimeAfter hours
Closed: 21 қыр., 16:00:00 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
360,42 $
High
367,00 $
Low
358,24 $
Mkt. cap
43,07 млрд
Avg. vol.
397,09 м.
Volume
488,98 м.
52-wk high
385,22 $
52-wk low
253,95 $
Beta
0,51
Shares outstanding
109,79 млн
No. of employees
12 мың
Open
360,42 $
High
367,00 $
Low
358,24 $
Mkt. cap
43,07 млрд
Avg. vol.
397,09 м.
Volume
488,98 м.
52-wk high
385,22 $
52-wk low
253,95 $
Beta
0,51
Shares outstanding
109,79 млн
No. of employees
12 мың
News stories
From web sources and news partners
TipRanks
·
9 сағат бұрын
Sonrotoclax Safety Study Completion Signals Next Steps for BeOne Medicines
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 мың
Founded2010 ж. 28 қаз.
Headquarters-
Sector-
Websitebeonemedicines.com